Search

everythinglearnresearchcommunity

for

Search:↓

Rare ovarian tumors can cause hyperandrogenism, even if imaging appears normal.

Finasteride may help postmenopausal women with hair loss but is not effective for all and should be used cautiously in premenopausal women.

Bilateral ovarian hyperthecosis is a rare but treatable cause of increased facial hair in postmenopausal women.

A postmenopausal woman's increased male hormone levels were successfully treated with surgery.

Patterned hair loss is relatively common in women and not usually a sign of serious health issues.

UK medical students lack dermatology education, liver biopsy patients with risk factors show more fibrosis, and certain fungi resist drugs due to melanin; genetics may influence female hair loss.

Using GnRHa agonists helps diagnose and treat ovarian hyperthecosis when surgery isn't possible.

"Male-pattern" hair loss is common in women, especially after menopause, and doesn't always mean there's a problem with hormone balance.

Hormones significantly affect women's sexual function, and more research is needed to improve treatments for sexual dysfunction with minimal side effects.

The review suggests there's no agreed treatment for Frontal Fibrosing Alopecia, but hydroxychloroquine and 5a-reductase inhibitors are most effective. New treatments like platelet-rich plasma and LED light could help if standard treatments fail.

The first in-prison dermatology clinic in the U.S. faced challenges and found certain skin conditions common among inmates, with rare cases of serious skin cancer.

Finasteride can slow hair loss and promote growth in postmenopausal women.

Frontal fibrosing alopecia is a hair loss condition in postmenopausal women, similar to lichen planopilaris, with ineffective treatments.

MK-0773 safely increased muscle mass but did not improve muscle strength or function in elderly women with sarcopenia.

Postmenopausal frontal fibrosing alopecia is a type of hair loss in postmenopausal women that may stop on its own but has no effective treatment.

Taking DHEA for a year is generally safe for postmenopausal women but may cause acne and more facial hair without improving metabolism or aging.

Finasteride 5 mg/day effectively treats hair loss in postmenopausal women without hyper-androgenism.

The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.

Selective Androgen Receptor Modulators (SARMs) are drugs that can control the effects of androgens in different tissues, potentially having fewer side effects and promising for treating various conditions.

Chinese women with PCOS have higher androgen levels, which change with age and weight.

DHT reduces a cell's ability to promote hair growth, while 3D culture without DHT improves it.

Androgen deprivation therapy for prostate cancer can cause sexual, physical, and psychological side effects, and doctors should manage these carefully.

Estrogen Receptor ß (ERß) is the main hormone controller in human skin and hair follicles, not Estrogen Receptor α (ERα) or the Androgen Receptor (AR).

A new gene, JMJD1C, may affect testosterone levels in men.

The research found that anovulatory young women have higher androgen and hormone levels than those who ovulate, suggesting immature hormonal regulation rather than a specific condition.

Flutamide improves female hair loss when other treatments fail, but may cause liver toxicity.

Oral contraceptives lower testosterone levels in women, especially those with certain genetic traits, and may be linked to increased breast cancer risk.

DHT affects bone growth by altering gene activity in osteoblasts, potentially complicating steroid use.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.